Changes in molecular forms of prostate-specific antigen during treatment with finasteride
- 31 October 2002
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 90 (7), 672-677
- https://doi.org/10.1046/j.1464-410x.2002.03002.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Prostate–Specific Antigen Complexed to α1–Antichymotrypsin in the Early Detection of Prostate CancerEuropean Urology, 2000
- Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trialUrology, 1998
- Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasterideUrology, 1997
- Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening populationUrology, 1996
- MedCalc: a new computer program for medical statisticsComputer Methods and Programs in Biomedicine, 1995
- Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new eraUrology, 1995
- Effect of finasteride on prostate-specific antigen densityUrology, 1994
- Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate CancerJournal of Urology, 1993
- The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasiaThe Prostate, 1993
- Enzymatic activity of prostate‐specific antigen and its reactions with extracellular serine proteinase inhibitorsEuropean Journal of Biochemistry, 1990